Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol vs Hydralazine in Severe Preeclampsia
NCT06360601Phase 2Recruiting
- Sponsor
- Tanta University
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in preeclampsia comparing Labetalol Group with Hydralazine Group (2 arms). Primary endpoint: Cerebral blood flow. Started Apr 2024; status: recruiting.
02
Drugs
labetalolhydralazine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT06360601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360601.